Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 1/2020

01-01-2020 | Primary Sclerosing Cholangitis | Original Article

Effects of Pristine C60 Fullerenes on Liver and Pancreas in α-Naphthylisothiocyanate-Induced Cholangitis

Authors: Halyna M. Kuznietsova, Natalia V. Dziubenko, Oksana V. Lynchak, Tetyana S. Herheliuk, Dmytro K. Zavalny, Olga V. Remeniak, Yuriy I. Prylutskyy, Uwe Ritter

Published in: Digestive Diseases and Sciences | Issue 1/2020

Login to get access

Abstract

Background

A significant role in pathogenesis of cholangitis is attributed to excessive reactive oxygen species production and oxidative stress. Therefore, antioxidants could be promising therapeutics.

Aims

The effects of powerful free radical scavenger C60 fullerene on hepatic and pancreatic manifestations of acute and chronic cholangitis in rats were aimed to be discovered.

Methods

Acute (AC, 3 days) and chronic (CC, 28 days) cholangitis models were simulated by single (AC) and 4 weekly (CC) α-naphthylisothiocyanate per os administrations. Pristine C60 fullerene aqueous colloid solution (C60FAS, 0.15 mg/ml, size of aggregates 1.2–100 nm) was administered either per os or intraperitoneally at a dose of 0.5 mg/kg C60 fullerene daily (AC) and every other day (CC). Prednisolone was used as a reference. Liver and pancreas autopsies were analyzed, and blood serum biochemical markers were measured. Pan-cytokeratin expression in HepG2 cells was assessed after 48-h incubation with C60FAS.

Results

On AC, C60FAS normalized elevated bilirubin, alkaline phosphatase, and triglycerides, diminished fibrotic alterations in liver, and improved pancreas state when applied by both ways. Additionally, C60FAS per os significantly reduced the signs of inflammation in liver and pancreas. On CC, C60FAS also mitigated liver fibrosis and inflammation, improved pancreas state, and normalized alkaline phosphatase and triglycerides. The remedy effect of C60FAS was more expressed compared to that of prednisolone on both models. Furthermore, C60FAS inhibited pan-cytokeratin expression in HepG2 cells in a dose-dependent manner.

Conclusion

Pristine C60 fullerene inhibits liver inflammation and fibrogenesis and partially improved liver and pancreas state under acute and chronic cholangitis.
Literature
1.
Molodecky NA, Kareemi H, Parab R, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53:1590–1599.PubMed
2.
Sirpal S, Chandok N. Primary sclerosing cholangitis: diagnostic and management challenges. Clin Exp Gastroenterol. 2017;10:265–273.PubMedPubMedCentral
3.
Hirschfield GM, Beuers U, Corpechot C, et al. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145–172.
4.
Zhu GQ, Shi KQ, Huang GQ, et al. A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis. Oncotarget. 2015;6:26757–26769.PubMedPubMedCentral
5.
6.
Islam MA, Alam F, Solayman M, et al. Dietary phytochemicals: natural swords combating inflammation and oxidation-mediated degenerative diseases. Oxid Med Cell Longev. 2016;2016:5137431.PubMedPubMedCentral
7.
Morrya J, Ngamcherdtrakula W, Yantasee W. Oxidative stress in cancer and fibrosis: opportunity for therapeutic intervention with antioxidant compounds, enzymes, and nanoparticles. Redox Biol. 2017;11:240–253.
8.
Gharbi N, Pressac M, Hadchouel M, et al. [60] Fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett. 2005;5:2578–2585.PubMed
9.
Lynchak OV, Prylutskyy YI, Rybalchenko VK, et al. Comparative analysis of the antineoplastic activity of C60 fullerene with 5-fluorouracil and pyrrole derivative in vivo. Nanoscale Res Lett. 2017;12:8.PubMedPubMedCentral
10.
Eswaran SV. Water soluble nanocarbon materials: a panacea for all? Curr Sci. 2018;114:1846–1850.
11.
Prylutskyy YI, Vereshchaka IV, Maznychenko AV, et al. C60 fullerene as promising therapeutic agent for correcting and preventing skeletal muscle fatigue. J Nanobiotechnol. 2017;15:8.
12.
Hendrickson OD, Morozova OV, Zherdev AV, et al. Study of distribution and biological effects of fullerene C60 after single and multiple intragastrical administrations to rats. Fuller Nanotub Carbon Nanostruct. 2015;23:658–668.
13.
Sumner SCJ, Snyder RW, Wingard C, et al. Distribution and biomarkers of carbon-14-labeled fullerene C60 ([14C(U)]C60) in female rats and mice for up to 30 days after intravenous exposure. J Appl Toxicol. 2015;35:1452–1464.PubMedPubMedCentral
14.
Halenova TI, Vareniuk IM, Roslova NM, et al. Hepatoprotective effect of orally applied water-soluble pristine C60 fullerene against CCl4-induced acute liver injury in rats. RSC Adv. 2016;6:100046–100055.
15.
Byelinska IV, Kuznietsova HM, Dziubenko NV, et al. Effect of C60 fullerenes on the intensity of colon damage and hematological signs of ulcerative colitis in rats. Mater Sci Eng C. 2018;93:505–517.
16.
17.
Prylutskyy YI, Yashchuk VM, Kushnir KM, et al. Biophysical studies of fullerene-based composite for bio-nanotechnology. Mater Sci Eng C. 2003;23:109–111.
18.
Ritter U, Prylutskyy YI, Evstigneev MP, et al. Structural features of highly stable reproducible C60 fullerene aqueous colloid solution probed by various techniques. Fuller Nanotub Carbon Nanostruct. 2015;23:530–534.
19.
Fickert P, Pollheimer MJ, Beuers U, et al. Characterization of animal models for primary sclerosing cholangitis (PSC). J Hepatol. 2014;60:1290–1303.PubMedPubMedCentral
20.
Bothe MK, Meyer C, Mueller U, et al. Characterization of a rat model of moderate liver dysfunction based on alpha-naphthylisothiocyanate-induced cholestasis. J Toxicol Sci. 2017;42:715–721.PubMed
21.
22.
Cogliati B, Crespo Yanguas S, da Silva TC, et al. Connexin32 deficiency exacerbates carbon tetrachloride-induced hepatocellular injury and liver fibrosis in mice. Toxicol Mech Methods. 2016;26:362–370.PubMedPubMedCentral
23.
Kawa S, Hamano H, Umemura T, et al. Sclerosing cholangitis associated with autoimmune pancreatitis. Hepatol Res. 2007;37:S487–S495.PubMed
24.
Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39:44–84.PubMed
25.
Grattagliano I, Calamita G, Cocco T, et al. Pathogenic role of oxidative and nitrosative stress in primary biliary cirrhosis. WJG. 2014;20:5746–5759.PubMed
26.
Prylutskyy Y, Bychko A, Sokolova V, et al. Interaction of C60 fullerene complexed to doxorubicin with model bilipid membranes and its uptake by HeLa Cells. Mater Sci Eng C. 2016;59:398–403.
27.
Franskevych D, Palyvoda K, Petukhov D, et al. Fullerene C60 penetration into leukemic cells and its photoinduced cytotoxic effects. Nanoscale Res Lett. 2017;12:40.PubMedPubMedCentral
28.
Yang H, Ramani K, Xia M, et al. Dysregulation of glutathione synthesis during cholestasis in mice: molecular mechanisms and therapeutic implications. Hepatology. 2009;49:1982–1991.PubMedPubMedCentral
29.
Markiewski MM, DeAngelis RA, Lambris JD. Liver inflammation and regeneration: two distinct biological phenomena or parallel pathophysiological processes. Mol Immunol. 2006;43:45–56.PubMed
30.
den Broeder AA, Verhoef LM, Fransen J, et al. Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial. Trials. 2017;18:403.
31.
Piróg M, Jach R, Undas A. Effects of ultra-low-dose versus standard hormone therapy on fibrinolysis and thrombin generation in postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 2017;217:77–82.PubMed
32.
Boldyreva LB. A theoretical approach to selection of a biologically active substance in ultra-low doses for effective action on a biological system. Homeopathy. 2018;107:137–142.PubMed
33.
Didenko G, Prylutska S, Kichmarenko Y, et al. Evaluation of the antitumor immune response to C60 fullerene. Mat.-wiss u Werkstofftech. 2013;44:124–128.
34.
Turabekova M, Rasulev B, Theodore M, et al. Immunotoxicity of nanoparticles: a computational study suggests that CNTs and C60 fullerenes might be recognized as pathogens by Toll-like receptors. Nanoscale. 2014;6:3488–3495.PubMed
35.
Skivka LM, Prylutska SV, Rudyk MP, et al. C60 fullerene and its nanocomplexes with anticancer drugs modulate circulating phagocyte functions and dramatically increase ROS generation in transformed monocytes. Cancer Nanotechnol. 2018;9:8.PubMedPubMedCentral
36.
Huebener P, Schwabe RF. Regulation of wound healing and organ fibrosis by Toll-like receptors. Biochim Biophys Acta. 2013;1832:1005–1017.PubMed
37.
38.
Shershakova N, Baraboshkina E, Andreev S, et al. Anti-inflammatory effect of fullerene C60 in a mice model of atopic dermatitis. J Nanobiotechnol. 2016;14:8.
39.
Libbrecht L, Roskams T. Hepatic progenitor cells in human liver diseases. Semin Cell Dev Biol. 2002;13:389–396.PubMed
40.
Nygard IE, Mortensen KE, Hedegaard J, et al. Tissue remodelling following resection of porcine liver. Biomed Res Int. 2015;2015:248920.PubMedPubMedCentral
41.
Wang S, Lee Y, Kim J, et al. Potential role of Hedgehog pathway in liver response to radiation. PLoS ONE. 2013;8:e74141.PubMedPubMedCentral
42.
Li J, Chen L, Zhang X, et al. Detection of circulating tumor cells in hepatocellular carcinoma using antibodies against asialoglycoprotein receptor, carbamoyl phosphate synthetase 1 and pan-cytokeratin. PLoS ONE. 2014;9:e96185.PubMedPubMedCentral
43.
Affo S, Yu LX, Schwabe RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol. 2016;12:153–186.PubMedPubMedCentral
44.
Tabibian JH, Trussoni CE, O’Hara SP, et al. Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis. Lab Invest. 2014;94:1126–1133.PubMedPubMedCentral
45.
Chougule P, Sumitran-Holgersson S. Cytokeratins of the liver and intestine epithelial cells during development and disease. In: Hamilton G, ed. Cytokeratins—Tools in Oncology. InTech; 2012. https://​doi.​org/​10.​5772/​33491.
46.
Ranganathan P, Jayakumar C, Manicassamy S, et al. CXCR46 knockout mice are protected against DSS-colitis-induced acute kidney injury and inflammation. Am J Physiol Renal Physiol. 2013;305:F1422–F1427.PubMedPubMedCentral
Metadata
Title
Effects of Pristine C60 Fullerenes on Liver and Pancreas in α-Naphthylisothiocyanate-Induced Cholangitis
Authors
Halyna M. Kuznietsova
Natalia V. Dziubenko
Oksana V. Lynchak
Tetyana S. Herheliuk
Dmytro K. Zavalny
Olga V. Remeniak
Yuriy I. Prylutskyy
Uwe Ritter
Publication date
01-01-2020
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2020
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05730-3

Other articles of this Issue 1/2020

Digestive Diseases and Sciences 1/2020 Go to the issue

Original Article

Anorectal Function After Ileo-Rectal Anastomosis Is Better than Pelvic Pouch in Selected Ulcerative Colitis Patients

Original Article

Computed Tomography Findings as a Novel Predictor of Alcohol-Associated Hepatitis Outcomes

Original Article

County Rankings Have Limited Utility When Predicting Liver Transplant Outcomes

Original Article

Acute Colchicine Poisoning Causes Endotoxemia via the Destruction of Intestinal Barrier Function: The Curative Effect of Endotoxin Prevention in a Murine Model

Original Article

Endoscopic Variceal Sequential Ligation Does Not Increase Risk of Gastroesophageal Reflux Disease in Cirrhosis Patients

UNM CLINICAL CASE CONFERENCES

As the Worm Turns: A Globally Prevalent Cause of Chronic Diarrhea
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits